Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in ERBB2-Positive Breast Cancer
6/24/2021
0:00
13:01
Interview with Thomas Hatschek, MD, PhD, author of Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial
More episodes from "JAMA Oncology Author Interviews"
Don't miss an episode of “JAMA Oncology Author Interviews” and subscribe to it in the GetPodcast app.